Literature DB >> 8077369

Effects of finasteride, a 5 alpha-reductase inhibitor, on circulating androgens and gonadotropin secretion in hirsute women.

F Fruzzetti1, D de Lorenzo, D Parrini, C Ricci.   

Abstract

An oral 5-mg dose of finasteride, a 5 alpha-reductase inhibitor, was administered for 3 months to 10 hirsute women to determine the effect on gonadotropin secretion, on basal and stimulated androgen secretion, and on hair growth. Hair growth was assessed by the Ferriman-Gallwey score. All of the above determinations were evaluated before and after 1 and/or 3 months of finasteride treatment. Basal and GnRH-stimulated gonadotropin secretions were not affected. Indeed, finasteride did not modify the pulsatility of LH secretion. No change was seen in estradiol, PRL, free testosterone, androstenedione, dehydroepiandrosterone sulfate, and sex hormone-binding globulin concentrations. Serum concentrations of cortisol (F) were significantly reduced after 1 month of finasteride treatment. The F levels returned to pretreatment levels after 3 months. Plasma levels of dihydrotestosterone and 3 alpha-androstanediol glucuronide significantly decreased during finasteride treatment. A significant increase in testosterone concentrations was observed after 3 months. Finasteride did not modify the responses of testosterone, androstenedione, and dehydroepiandrosterone sulfate to ACTH-(1-24) injection. Conversely, finasteride blunted the F response to corticotropin stimulation. Three months of finasteride treatment significantly decreased the Ferriman-Gallwey score. In conclusion, finasteride significantly decreased dihydrotestosterone and hair growth in hirsute women without negatively affecting gonadotropin secretion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8077369     DOI: 10.1210/jcem.79.3.8077369

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies.

Authors:  Raquel N Rozner; Azael Freites-Martinez; Jerry Shapiro; Eliza B Geer; Shari Goldfarb; Mario E Lacouture
Journal:  Breast Cancer Res Treat       Date:  2018-11-22       Impact factor: 4.872

Review 2.  A risk-benefit assessment of pharmacological therapies for hirsutism.

Authors:  E Carmina
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 3.  Adverse Effects and Safety of 5-alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review.

Authors:  Jason M Hirshburg; Petra A Kelsey; Chelsea A Therrien; A Carlo Gavino; Jason S Reichenberg
Journal:  J Clin Aesthet Dermatol       Date:  2016-07-01

4.  Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism.

Authors:  Y Sahin; F Bayram; F Keleştimur; I Müderris
Journal:  J Endocrinol Invest       Date:  1998-06       Impact factor: 4.256

5.  Effect of finasteride in idiopathic hirsutism.

Authors:  E Faloia; S Filipponi; V Mancini; S Di Marco; F Mantero
Journal:  J Endocrinol Invest       Date:  1998-11       Impact factor: 4.256

6.  Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial.

Authors:  Alan R Kristal; Jeannette M Schenk; YoonJu Song; Kathryn B Arnold; Marian L Neuhouser; Phyllis J Goodman; Daniel W Lin; Frank Z Stanczyk; Ian M Thompson
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

7.  Relative adrenal insufficiency in mice deficient in 5α-reductase 1.

Authors:  Dawn E W Livingstone; Emma M Di Rollo; Chenjing Yang; Lucy E Codrington; John A Mathews; Madina Kara; Katherine A Hughes; Christopher J Kenyon; Brian R Walker; Ruth Andrew
Journal:  J Endocrinol       Date:  2014-05-28       Impact factor: 4.286

8.  Prolonged use of finasteride-induced gonadal sex steroids alterations, DNA damage and menstrual bleeding in women.

Authors:  Gadah Albasher; May Bin-Jumah; Saleh Alfarraj; Fatimah Al-Otibi; Nouf K Al-Sultan; Saud Alarifi; Saad Alkahtani; Nahed S Alharthi; Wedad S Al-Qahtani
Journal:  Biosci Rep       Date:  2020-02-28       Impact factor: 3.840

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.